Press "Enter" to skip to content

Novavax COVID Vaccines Should Carry Heart Inflammation Warning, EU Says

BMegan Redshaw

The European Medicines Agency (EMA) today recommended adding a warning for two types of heart inflammation to Novavax’s COVID-19 vaccine, marketed under the brand names Nuvaxovid and Covovax, based on a small number of cases reported in those who received the vaccine.

According to a statement, the EMA’s Pharmacovigilance Risk Assessment Committee — responsible for assessing and monitoring the safety of human medicines — concluded that “myocarditis and pericarditis can occur following vaccination with Nuvaxovid.”

“The Committee is therefore recommending listing myocarditis and pericarditis as new side effects in the product information for Nuvaxovid, together with a warning to raise awareness among healthcare professionals and people receiving this vaccine,” the statement said…

Read More Here

News PDF Archives – Jellyfish.NEWS

Be First to Comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Breaking News: